Home/Filings/4/0001796536-25-000005
4//SEC Filing

Sanders Corazon (Corsee) D. 4

Accession 0001796536-25-000005

CIK 0001651308other

Filed

Nov 30, 7:00 PM ET

Accepted

Dec 1, 4:57 PM ET

Size

12.1 KB

Accession

0001796536-25-000005

Insider Transaction Report

Form 4
Period: 2025-11-26
Transactions
  • Exercise/Conversion

    American Depositary Shares

    2025-11-26$159.03/sh+2,627$417,7722,627 total
  • Sale

    American Depositary Shares

    2025-11-26$340.20/sh1,823$620,185804 total
  • Sale

    American Depositary Shares

    2025-11-26$342.47/sh804$275,3490 total
  • Exercise/Conversion

    Share Option (Right to Buy)

    2025-11-2634,1510 total
    Exercise: $12.23Exp: 2034-06-04Ordinary Shares (34,151 underlying)
Holdings
  • Ordinary Shares

    57,226
Footnotes (5)
  • [F1]Each American Depositary Share represents 13 Ordinary Shares.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  • [F4]The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
  • [F5]The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Issuer

BeOne Medicines Ltd.

CIK 0001651308

Entity typeother

Related Parties

1
  • filerCIK 0001796536

Filing Metadata

Form type
4
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 4:57 PM ET
Size
12.1 KB